Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study
Autore:
Scorza, R; Caronni, M; Mascagni, B; Berruti, V; Bazzi, S; Micallef, E; Arpaia, G; Sardina, M; Origgi, L; Vanoli, M;
Indirizzi:
Univ Milan, IRCCS Osped Maggiore, I-20122 Milan, Italy Univ Milan Milan Italy I-20122 RCCS Osped Maggiore, I-20122 Milan, Italy Niguarda Ca Granda Hosp, Resp Physiopathol Serv, Milan, Italy Niguarda Ca Granda Hosp Milan Italy esp Physiopathol Serv, Milan, Italy S Carlo B Gen Hosp, Vasc & Thrombot Pathol Dept, Milan, Italy S Carlo B Gen Hosp Milan Italy asc & Thrombot Pathol Dept, Milan, Italy
Titolo Testata:
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
fascicolo: 5, volume: 19, anno: 2001,
pagine: 503 - 508
SICI:
0392-856X(200109/10)19:5<503:EOLCIT>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONNECTIVE-TISSUE DISEASES; INTRAVENOUS ILOPROST; CYTOKINE PRODUCTION; DIFFUSING-CAPACITY; SCLERODERMA; SECONDARY; INFUSION; PATHOGENESIS; INVOLVEMENT; NIFEDIPINE;
Keywords:
systemic sclerosis; Raynaud's phenomenon; iloprost; controlled clinical trial;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Scorza, R Univ Milan, IRCCS Osped Maggiore, Via F Sforza 35, I-20122 Milan, Italy Univ Milan Via F Sforza 35 Milan Italy I-20122 122 Milan, Italy
Citazione:
R. Scorza et al., "Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study", CLIN EXP RH, 19(5), 2001, pp. 503-508

Abstract

Objective Iloprost is a stable prostacyclin analogue which has been shown to be effective in the short-term symptomatic treatment of Raynaud's phenomenon (RP) secondary to systemic sclerosis (SSc). The aim of this study was to evaluate the effects of long-term cyclic therapy with iloprost in comparison with nifedipine on the skin score, pulmonary function and Raynaud's severity score in patients with SSc and RP. Methods We conducted a 12-month prospective, randomised, parallel-group, blind-observer trial to compare the effects of intravenously infused iloprost (2 ng/kg/min on 5 consecutive days over a period of 8 hours/day and subsequently for 8 hours on one day every 6 weeks) with those of conventional vasodilating therapy with nifedipine (40 mg/day per os) in 46 patients with SSc and RP. Results At 12 months, iloprost but not nifedipine reduced the skin score (iloprost: from 13.26 +/- 2.05 to 9.26 +/- 1.32, p = 0.002; nifedipine:from 10.83 +/- 2.09 to 12.17 +/- 3.02, p = n.s.; iloprost vs nifedipine: p = 0.016) and the RP severity score (iloprost:from 2.17 +/- 0.2 to 1.22 +/- 0.13,p = 0.02 vs baseline; nifedipine:from 2.08 +/- 0.34 to 1.33 +/- 0.22, p = n.s.). Carbon monoxide diffusing capacity (DLCO), expressed as % of the predicted normal value, worsened significantly in the nifedipine group (from 69.6 +/- 7.4% to 61.5 +/- 6.5%, p = 0.044) and remained stable in patients treated with iloprost (from 53.2 +/- 4.8 to 56.0 +/- 4.6%, iloprost vs nifedipine: p = 0.026). Conclusion In SSc patients, cyclic intravenous iloprost infusion is able to control vasospastic disease. Our results suggest that it might also act as a disease-modifying agent, as it seems to improve the course of the disease. Further studies principally focused on organ involvement and the natural history of the disease are needed to confirm our results.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/21 alle ore 12:39:42